Joint approach.
Palmer
Kim
K
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D042241:Early Diagnosis; D006801:Humans; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D001688:Biological Products; D019947:Receptors, Interleukin-6; D014409:Tumor Necrosis Factor-alpha